

- Announce topline data from the Phase 2 Safety and Immunogenicity trial of the RSV F Vaccine in older adults

- Provide an Update on the RSV F Vaccine Development Program

GAITHERSBURG, Md., July 17, 2017 /PRNewswire/ -- Novavax, Inc. (Nasdaq:NVAX) today announced it will host a conference call and webcast on Monday, July 24, 2017, at 4:30 p.m. ET. Novavax anticipates receiving results and announcing topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults (60 years of age and older). In addition, management will provide an update on its prior Phase 2 and Phase 3 clinical trials in older adults and well as its RSV Phase 3 clinical trial for infants via maternal immunization, known as Prepare™, which continues to experience significant acceleration in enrollment and enhanced momentum heading into its third global season.

Preliminary webcast agenda:

1. Announce topline data from the Phase 2 safety and immunogenicity trial in Older Adults
2. Provide additional findings from prior Phase 2 and Phase 3 clinical trials in Older Adults
3. Update on the Prepare™ trial for Infants via Maternal Immunization

Conference call details are as follows:

Date: Monday, July 24, 2017

Time: 4:30 p.m. U.S. Eastern Time (ET)

Dial-in number: (877) 212-6076 (Domestic) or (707) 287-9331 (International)

Passcode: 54820069

Webcast: www.novavax.com, "Investors"/ "Events"

Conference call and webcast replay:

Dates: Starting at 7:30 p.m. ET, July 24, 2017, until 7:30 p.m. ET, July 31, 2017

Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)

Passcode: 54820069

Webcast: www.novavax.com, "Investors"/ "Events", until October 24, 2017

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Contact:

[Investor Relations](#)

Novavax, Inc.

Andrea N. Flynn, Ph.D.

Director, Investor Relations

ir@novavax.com

240-268-2000

Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media

Russo Partners, LLC
David Schull
Maggie Beller
david.schull@russopartnersllc.com
maggie.beller@russopartnersllc.com
212-845-4271

View original content: <http://www.prnewswire.com/news-releases/novavax-to-host-an-rsv-f-vaccine-update-conference-call-and-webcast-on-july-24-2017-at-430-pm-300489222.html>

<https://ir.novavax.com/2017-07-17-Novavax-to-Host-an-RSV-F-Vaccine-Update-Conference-Call-and-Webcast-on-July-24-2017-at-4-30-PM>